Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer

A 10-year single institution experience with a racially diverse urban population

Eirwen M. Miller, Joan Tymon-Rosario, Xianhong Xie, Xiaonan (Nan) Xue, Gregory M. Gressel, Devin T. Miller, Dennis Yi-Shin Kuo, Nicole S. Nevadunsky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: The goal of our study was to define utilization and clinical results of intraperitoneal (IV/IP) compared to intravenous (IV) chemotherapy in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. Methods: After IRB approval, all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at our institution from 2005 to 2016 were identified. Death was verified by the National Social Security Death Index. Patients who received at least one IV/IP cycle were analyzed in the IV/IP cohort. Kaplan-Meier and Cox proportional hazards models were performed. Results: 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33. months) were identified. 51% and 49% of patients received IV/IP and IV chemotherapy, respectively. 27%, 22%, and 39% of patients were of white, black, and other race. Compared with IV chemotherapy only, IV/IP chemotherapy was associated with longer OS (log rank <. 0.002) and IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR = 0.31, 95% CI 0.16-0.62, P <. 0.001). The median overall survival for the IV/IP and IV groups was 76. months (95% CI 62 - not estimated) and 38. months (95% CI 30-55), respectively. There was a trend toward higher risk of death for patients who completed fewer than 6. cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR = 3.2, 95% CI 0.98-9.27 (P = 0.05). No differences in patient or tumor characteristics were identified between these two groups of patients. Conclusions: In our racially diverse urban patients, 50% of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

Urban Population
antineoplaston A10
Drug Therapy
Ovarian epithelial cancer
Security Measures
Survival
Social Security
Research Ethics Committees
Proportional Hazards Models

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

@article{4b400ce9b77f452283c7dfd94adb419f,
title = "Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population",
abstract = "Objectives: The goal of our study was to define utilization and clinical results of intraperitoneal (IV/IP) compared to intravenous (IV) chemotherapy in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. Methods: After IRB approval, all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at our institution from 2005 to 2016 were identified. Death was verified by the National Social Security Death Index. Patients who received at least one IV/IP cycle were analyzed in the IV/IP cohort. Kaplan-Meier and Cox proportional hazards models were performed. Results: 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33. months) were identified. 51{\%} and 49{\%} of patients received IV/IP and IV chemotherapy, respectively. 27{\%}, 22{\%}, and 39{\%} of patients were of white, black, and other race. Compared with IV chemotherapy only, IV/IP chemotherapy was associated with longer OS (log rank <. 0.002) and IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR = 0.31, 95{\%} CI 0.16-0.62, P <. 0.001). The median overall survival for the IV/IP and IV groups was 76. months (95{\%} CI 62 - not estimated) and 38. months (95{\%} CI 30-55), respectively. There was a trend toward higher risk of death for patients who completed fewer than 6. cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR = 3.2, 95{\%} CI 0.98-9.27 (P = 0.05). No differences in patient or tumor characteristics were identified between these two groups of patients. Conclusions: In our racially diverse urban patients, 50{\%} of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.",
author = "Miller, {Eirwen M.} and Joan Tymon-Rosario and Xianhong Xie and Xue, {Xiaonan (Nan)} and Gressel, {Gregory M.} and Miller, {Devin T.} and Kuo, {Dennis Yi-Shin} and Nevadunsky, {Nicole S.}",
year = "2017",
doi = "10.1016/j.ygyno.2017.07.129",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer

T2 - A 10-year single institution experience with a racially diverse urban population

AU - Miller, Eirwen M.

AU - Tymon-Rosario, Joan

AU - Xie, Xianhong

AU - Xue, Xiaonan (Nan)

AU - Gressel, Gregory M.

AU - Miller, Devin T.

AU - Kuo, Dennis Yi-Shin

AU - Nevadunsky, Nicole S.

PY - 2017

Y1 - 2017

N2 - Objectives: The goal of our study was to define utilization and clinical results of intraperitoneal (IV/IP) compared to intravenous (IV) chemotherapy in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. Methods: After IRB approval, all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at our institution from 2005 to 2016 were identified. Death was verified by the National Social Security Death Index. Patients who received at least one IV/IP cycle were analyzed in the IV/IP cohort. Kaplan-Meier and Cox proportional hazards models were performed. Results: 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33. months) were identified. 51% and 49% of patients received IV/IP and IV chemotherapy, respectively. 27%, 22%, and 39% of patients were of white, black, and other race. Compared with IV chemotherapy only, IV/IP chemotherapy was associated with longer OS (log rank <. 0.002) and IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR = 0.31, 95% CI 0.16-0.62, P <. 0.001). The median overall survival for the IV/IP and IV groups was 76. months (95% CI 62 - not estimated) and 38. months (95% CI 30-55), respectively. There was a trend toward higher risk of death for patients who completed fewer than 6. cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR = 3.2, 95% CI 0.98-9.27 (P = 0.05). No differences in patient or tumor characteristics were identified between these two groups of patients. Conclusions: In our racially diverse urban patients, 50% of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.

AB - Objectives: The goal of our study was to define utilization and clinical results of intraperitoneal (IV/IP) compared to intravenous (IV) chemotherapy in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. Methods: After IRB approval, all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at our institution from 2005 to 2016 were identified. Death was verified by the National Social Security Death Index. Patients who received at least one IV/IP cycle were analyzed in the IV/IP cohort. Kaplan-Meier and Cox proportional hazards models were performed. Results: 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33. months) were identified. 51% and 49% of patients received IV/IP and IV chemotherapy, respectively. 27%, 22%, and 39% of patients were of white, black, and other race. Compared with IV chemotherapy only, IV/IP chemotherapy was associated with longer OS (log rank <. 0.002) and IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR = 0.31, 95% CI 0.16-0.62, P <. 0.001). The median overall survival for the IV/IP and IV groups was 76. months (95% CI 62 - not estimated) and 38. months (95% CI 30-55), respectively. There was a trend toward higher risk of death for patients who completed fewer than 6. cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR = 3.2, 95% CI 0.98-9.27 (P = 0.05). No differences in patient or tumor characteristics were identified between these two groups of patients. Conclusions: In our racially diverse urban patients, 50% of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85025458559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025458559&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.07.129

DO - 10.1016/j.ygyno.2017.07.129

M3 - Article

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -